Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Inclusion Criteria: * Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors); histologic confirmation of either the primary or metastatic site. * ECOG performance status of \< 1 * \> 4 weeks since completion of previous chemotherapy * \> 4 weeks since participation in any investigational drug study * Peripheral neuropathy of grade \< 1 * Patients must have failed a gemcitabine-containing regimen administered in the metastatic, adjuvant, or locally advanced setting. * Absolute neutrophil count (ANC) \> 1,500/mm3 * Hemoglobin \> 9.0gm/dl * Platelets \> 100,000/mm3 * Total bilirubin \< 2.0mg/dl * AST and alkaline phosphatase \< 5 x upper limit of normal (ULN) * Albumin \> 2.5gm/dl * CA 19-9 \> 1.5 x ULN Exclusion Criteria: * Prior therapy with taxane or with epidermal growth factor receptor (EGFR) inhibitors * More than one prior chemotherapy treatment * Clinically significant cardiac disease * Major surgery within 4 weeks of the start of study treatment * Evidence of central nervous system (CNS) metastases or carcinomatous meningitis or history of uncontrolled seizures, central nervous system disorders. * Uncontrolled serious medical or psychiatric illness * Pregnant or breast-feeding women * Other active malignancy * Inability to swallow tablets or evidence of a gastrointestinal malabsorption syndrome * Known severe hypersensitivity to Iressa * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St. John's wort. * History of severe hypersensitivity reaction to drugs formulated with polysorbate 80 * Any evidence of clinically active interstitial lung disease * Ascites requiring paracentesis